遼寧成大(600739.SH):成大生物在全國中小企業股份轉讓系統終止掛牌
格隆匯11月5日丨遼寧成大(600739.SH)公佈,遼寧成大生物股份有限公司(以下簡稱“成大生物”)為公司控股子公司。公司於2020年9月7日召開第九屆董事會第二十二次(臨時)會議審議通過了《關於公司所屬子公司附條件生效的向全國中小企業股份轉讓系統申請終止掛牌的議案》。
2020年9月25日,上海證券交易所科創板股票上市委員會2020年第80次審議會議同意成大生物在科創板首發上市申請。公司於2020年9月26日披露了《遼寧成大股份有限公司關於公司所屬子公司遼寧成大生物股份有限公司首次公開發行股票並在科創板上市申請通過上市委審議的公告》。
近日,成大生物收到全國中小企業股份轉讓系統有限責任公司出具的《關於同意遼寧成大生物股份有限公司股票終止在全國中小企業股份轉讓系統掛牌的函》,成大生物股票自2020年11月6日起終止在全國中小企業股份轉讓系統掛牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.